Effects of Yuzu (Citrus junos Siebold ex Tanaka) peel on the diet
Transcription
Effects of Yuzu (Citrus junos Siebold ex Tanaka) peel on the diet
journal of functional foods 10 (2014) 499–510 Available at www.sciencedirect.com ScienceDirect j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / j ff Effects of Yuzu (Citrus junos Siebold ex Tanaka) peel on the diet-induced obesity in a zebrafish model Liqing Zang a,*, Yasuhito Shimada b,c,d,e,f, Jumpei Kawajiri a, Toshio Tanaka b,c,d,e,f, Norihiro Nishimura a a Department of Translational Medical Science, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan b Department of Systems Pharmacology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan c Department of Molecular and Cellular Pharmacology, Pharmacogenomics, and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan d Mie University Medical Zebrafish Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan e Department of Bioinformatics, Mie University Life Science Research Center, 2-174 Edobashi, Tsu, Mie 5148507, Japan f Department of Omics Medicine, Mie University Industrial Technology Innovation Institute, 2-174 Edobashi, Tsu, Mie 514-8507, Japan A R T I C L E I N F O A B S T R A C T Article history: Effects of yuzu peel (Citrus junos Siebold ex Tanaka), yuzu pomace after hexane extraction, Received 7 March 2014 and auraptene on metabolic disorders in zebrafish with diet-induced obesity (DIO) were evalu- Received in revised form 31 July ated. All materials tested exhibited anti-obesity effects. Yuzu peel significantly suppressed 2014 the rise in plasma triacylglycerol (TG) and liver lipid accumulation. The hepatic mRNA ex- Accepted 7 August 2014 pression of pparab (peroxisome proliferator-activated receptor, alpha b) and its target genes were significantly upregulated by yuzu peel, which suggests enhanced fatty acid β-oxidation Keywords: in liver. In visceral adipose tissue, yuzu peel significantly increased the mRNA expression Anti-obesity of pparg (peroxisome proliferator-activated receptor, gamma) and adipoqb (adiponectin, C1Q Fatty acid oxidation and collagen domain containing, b), which play roles in adipose differentiation and main- PPARs tenance. Our findings suggest that yuzu peel exerts anti-obesity effects by activating hepatic Yuzu peel PPARα and adipocyte PPARγ pathways. Additionally, the anti-obesity effects of yuzu pomace Yuzu pomace suggest a novel application to achieve complete use of yuzu instead of disposal as indus- Zebrafish trial waste. © 2014 Elsevier Ltd. All rights reserved. 1. Introduction Obesity is one of the most challenging public health problems in developed countries and it is of growing concern in * Corresponding author. Tel.: +81 59 231 5405; fax: +81 59 231 5405. E-mail address: liqing@doc.medic.mie-u.ac.jp (L. Zang). http://dx.doi.org/10.1016/j.jff.2014.08.002 1756-4646/© 2014 Elsevier Ltd. All rights reserved. developing countries. The prevalence of obesity has increased so rapidly (worldwide obesity has nearly doubled since 1980) that it is now considered a global epidemic (WHO, 2013). Obesity increases the likelihood of various adverse health consequences, particularly cardiovascular diseases, type 2 diabetes 500 journal of functional foods 10 (2014) 499–510 mellitus, dyslipidaemia, nonalcoholic fatty liver, and certain types of cancer (Haslam & James, 2005). Dieting and physical exercise are the mainstays of treatment for obesity. If diet and exercise are not effective, anti-obesity drugs may be taken, in the context of a suitable diet, to reduce appetite or inhibit fat absorption (Aronne, Powell, & Apovian, 2011; Christensen, Kristensen, Bartels, Bliddal, & Astrup, 2007). However, most of these drugs are associated with side effects such as high blood pressure, restlessness, insomnia, and drug addiction (Bessesen, 2008). For this reason, a variety of natural products have been studied for their potential to treat obesity with minimal side effects (Hirai et al., 2010; Yun, 2010). Yuzu originated in China, but also grows wild in Japan and Korea. The fruit looks like a very small grapefruit with an uneven skin, but is rarely eaten as a fruit because of its tart flavour. Yuzu produces what has been described as a pleasant citrus fragrance with a floral overtone, and is widely used in Japanese and Korean cuisines. Examples include Yuzu-ponzu (a dressing made from soy sauce and yuzu juice), Yuzu-kosho (a seasoning made from yuzu peel, chili peppers and salt) and Yuja-cha (a traditional Korean herbal tea made from sliced yuzu peel and combined with honey or sugar prepared as fruit preserves or marmalade). Furthermore, yuzu has been used in traditional Chinese medicine as an aromatic stomachic and sweating medicine. A hot yuzu bath has been reported to improve blood circulation and prevent colds (Hirota et al., 2010). Yuzu is effective in preventing certain diseases owing to its antiinflammatory (Hirota et al., 2010), antioxidant (Yoo, Lee, Park, Lee, & Hwang, 2004), and anticarcinogenic (Kim et al., 2014; Sawamura, Wu, Fujiwara, & Urushibata, 2005) properties. Recently, the ethanol extract of yuzu peel was found to exert antidiabetic effects via AMPK (AMP-activated protein kinase) and PPARγ (peroxisome proliferator-activated receptor gamma) signalling both in vitro and in vivo (Kim et al., 2013). However, the underlying mechanisms of the anti-obesity activity of yuzu have not been explored. Zebrafish (Danio rerio) species are vertebrates, and have gained increased popularity as a model of human diseases because their organs and genetics are similar to those of humans (Lieschke & Currie, 2007; Shimada, Hirano, Nishimura, & Tanaka, 2012). Zebrafish is used as a model of lipid metabolism for lipid-related diseases because of its similarities to that in humans in terms of transport of fat and cholesterol by lipoproteins and storage as triacylglycerol (TG) in visceral, subcutaneous, and intramuscular adipocyte depots (Shimada et al., 2013; Stoletov et al., 2009). Moreover, a useful zebrafish model of diet-induced obesity (DIO) has been created and was found to be highly consistent with the obesity observed in humans and in rodent models of DIO (Oka et al., 2010). The overall gene expression profile of visceral adipose tissue is also consistent with those of humans and rodents. This zebrafish model of DIO has therefore been used to validate the antiobesity effects of natural products for their potential use in the treatment of human obesity (Hiramitsu et al., 2014; Tainaka et al., 2011). In this study, we investigated the effects of yuzu peel, yuzu pomace after hexane extraction, and auraptene (one of the bioactive compounds present in yuzu peel) on body weight, plasma TG, fat storage in the liver and adipose tissue, and expression of lipid metabolism-related genes in DIO zebrafish. 2. Materials and methods 2.1. Animals and maintenance Zebrafish species (AB strain; the Zebrafish International Research Centre, Eugene, OR, USA) were maintained under standard laboratory conditions at 28 °C with a light: dark cycle of 14:10 h (Westerfield, 2007). Fish were fed twice daily with commercial dry food (Hikari Tropical Fancy Guppy; Kyorin, Hyogo, Japan) and once daily with live Artemia nauplii (Kitamura, Kyoto, Japan). The zebrafish used in this study were 3-monthold females bred in our facility. 2.2. Preparation of yuzu peel, yuzu pomace, and auraptene-containing gluten granules Yuzu peel and pomace were provided by Tsuji Oil Mill Co., Ltd (Matsusaka, Mie, Japan). The fruit pulp of yuzu was removed and the peel was sliced and stored at −20 °C for ≤ 2 months. Hexane extraction was performed on the yuzu peel to extract the essential yuzu oil, and the remaining pomace was heated to 100 °C for 20 min to remove the residual hexane (1–2,000 ppm of hexane remained at this stage. Details for this analytical method are provided in Supplementary File S1). Samples were then stored at −20 °C until use. Before treatment of zebrafish, yuzu peel (containing essential oil) and pomace (not containing essential oil) were lyophilized and ground into granules using a mortar and a 700 µm mesh sieve (AS ONE Corporation, Osaka, Japan). After lyophilization, a trace amount of hexane (9.1 ppm) remained in pomace. For oral administration of auraptene to adult zebrafish, we used gluten as a carrier material. Auraptene (LKT Laboratories, St. Paul, MN, USA) was suspended in 50% ethanol and mixed with gluten powder (Wako Pure Chemicals, Osaka, Japan). The wet dough was kneaded, freeze-dried, and ground to granules according to methods described previously (Zang, Morikane, Shimada, Tanaka, & Nishimura, 2011). Two kinds of gluten granules were made containing 0.1% (low-auraptene, LA) and 0.2% (high-auraptene, HA) auraptene, respectively. Yuzu peel, pomace, and auraptene-containing gluten granules were prepared just before use and stored at 4 °C in an airtight container during the experimental period. 2.3. Quantification of bioactive compounds in yuzu peel and yuzu pomace Levels of the primary bioactive compounds in yuzu peel and pomace were quantified by Tsuji Oil Mill Co., Ltd (measurement of auraptene) and Japan Food Research Laboratories (Nagoya, Aichi, Japan) (Table 1). Auraptene, hesperidin and naringin were measured using high performance liquid chromatography (HPLC) (Ogawa et al., 2000). Limonene was measured using gas chromatography-mass spectrometry (GCMS) (Lesjak et al., 2014). Eriocitrin was measured using liquid chromatography-mass spectrometry (LC-MS/MS). Dietary fibre was measured using an enzymatic-gravimetric method (AOAC Official Methods of Analysis, 2000; Ajila & Rao, 2013). Details for these analysis methods are provided in Supplementary File S2. The major component of the essential oil extracted by 501 journal of functional foods 10 (2014) 499–510 Table 1 – Contents of the primary bioactive compounds in yuzu peel and pomace. Compound (units) Yuzu peel Yuzu pomace Referencec Auraptene (mg/g)a Limonene (mg/100 g)b Hesperidin (mg/100 g)b Naringin (mg/100 g)b Eriocitrin (mg/100 g)b Dietary fibre (g/100 g)b 0.3 ± 0.02 150.77 ± 5.21 (83%d) 92.57 ± 0.15 52.23 ± 0.21 ND 6.4 ± 0.02 0.1 ± 0.02 9.99 ± 0.46 127 ± 3.61 68.23 ± 0.6 1.01 ± 0.07 8.35 ± 0.08 0.375 73.16%e 74.47–96.24 81.51–98.1 ND 4.4 ± 0.3 Ogawa et al., 2000 Choi, 2006 Yoo, Lee, Park, Lee, & Hwang, 2004 Yoo, Lee, Park, Lee, & Hwang, 2004 Miyake, 2006 Yoo, Hwang, Park, & Moon, 2009 ND, <0.5 mg/100 g. a Data are the mean ± SD (n = 3) on a dry weight basis. b Data are the mean ± SD (n = 3) on a fresh weight basis. c Contents in yuzu peel. d Proportion of limonene in hexane-extracted yuzu peel oil. e Proportion of limonene in yuzu peel oil extracted using a cold-pressing method. hexane was limonene (83%, as measured by Tsuji Oil Mill Co., Ltd), with the remainder being aromatic compounds (data not shown). 2.4. Feeding zebrafish The experimental protocol for induction of obesity and administration of yuzu peel, pomace, and auraptene is shown in Supplementary Fig. S1. During the first 4 weeks, 3-month-old female zebrafish were randomly divided with 15 fish per 2 L tank for dietary restriction, which was performed by feeding once daily (approximately 4 mg/fish/day) with Hikari Tropical Fancy Guppy diet. After dietary restriction, zebrafish were assigned to one of six treatment groups (non-DIO, DIO, DIO + yuzu peel, DIO + yuzu pomace, DIO + LA, DIO + HA) with five fish per 2 L tank. The details for feeding the zebrafish are shown in Supplementary Table S1. Yuzu peel, pomace granules, auraptene-containing gluten granules were fed to zebrafish 20 min before Artemia feeding. During feeding, the tank water flow was stopped for 2 h. Leftover food was removed once daily by vacuuming to avoid water pollution. 2.5. Once the appropriate amount of blood was collected, suction was stopped. The needle was removed and the blood sample expelled from the needle onto a clean area of a piece of parafilm. Two microlitres of blood was obtained using a pipette set and then diluted with 6 µL of saline for determination of plasma TG concentration. The blood samples were centrifuged for 3 min at 680 g at room temperature and the plasma was harvested. TG was measured using a Wako L-type TG kit (Wako Pure Chemicals) according to the manufacturer’s protocol. 2.6. Feeding volume assay Feeding volume of Artemia was measured weekly during overfeeding treatment as previously described (Hasumura et al., 2012; Tainaka et al., 2011). Briefly, freshly hatched Artemia were uniformly suspended in the water, and then fed to zebrafish in a 2 L fish tank. For a blank control, Artemia were placed in a 2 L tank without zebrafish (i.e., containing only system water). After 2 h, the number of Artemia not eaten by the zebrafish was counted three times and subtracted from the number in the blank tank to determine the feeding volume in each tank. Measurement of body weight and plasma TG 2.7. The body weight of the zebrafish was measured weekly during the overfeeding treatment. Fish were fasted overnight and anesthetized by placing them in a tank containing 500 ppm of 2-phenoxyethanol (2-PE; Wako Pure Chemicals). Body weight (g) was measured after the body surface was dried with soft tissue paper (Kimwipe; Nippon Paper Crecia, Tokyo, Japan). At the end of the experiment, blood samples were collected from individual zebrafish as described previously (Zang, Shimada, Nishimura, Tanaka, & Nishimura, 2013). In brief, glass microcapillary needles were prepared by pulling a glass capillary (GD-1; outer diameter, 1.0 mm; Narishige, Tokyo, Japan) with a needle puller (PC-10; Narishige). The tips of needles were cut obliquely and heparinized using an aspirator tube assembly (Drummond, New Bethlehem, PA, USA). Before blood collection, the body surface of anaesthetized zebrafish was dried with soft tissue paper. The heparinized needle was inserted at 30–45° into the blood-collection site (along the body axis and posterior to the anus in the region of the dorsal aorta). Once the needle was felt to touch the spine, suction was applied to the mouthpiece-end of the aspiration tube to collect the blood. CT measurement of visceral adipose tissue volume After blood collection, zebrafish were euthanized by immersion in an ice–water bath (5 parts ice/1 part water at ≤4 °C) for ≥ 20 min (Matthews & Varga, 2012) and a 3D micro-CT scan was performed using an in vivo System R_mCT 3D micro-CT scanner (Rigaku, Tokyo, Japan) as described previously (Hasumura et al., 2012). The 3D images were reconstructed and viewed using i-View type R software (J. Morita Mfg, Kyoto, Japan), and visualized and analysed using CTAtlas Metabolic Analysis Ver. 2.03 software (Rigaku). Measurement of visceral adipose tissue volume was limited to the abdominal cavity, and the initial point of the abdominal cavity was set from the cleithrum to the anus. 2.8. Oil red O staining Scissors and forceps were used to strip off one side of the abdominal wall, which was then fixed in 4% formaldehyde solution in PBS (Histo-Fresh; FALMA, Tokyo, Japan) at 4 °C for 24 h. The fixed liver tissues were isolated and placed in 30% 502 journal of functional foods 10 (2014) 499–510 Table 2 – Primer pair sequences, accession numbers and product sizes of the studied genes. Gene name Zebrafish Human fasn acacb acadm acox1 pparab socs3b pparg adipoqb 18S rRNA FASN ACACB ACADM ACOX1 PPARα SOCS3 PPARγ ADIPOQ 18S rRNA a Accession number Forward primera Reverse primera Product size (bp) XM_005169478 XM_678989 NM_213010 NM_001005933 NM_001102567 NM_213304 NM_131467 BC165538 FJ915075 ATCTGTTCCTGTTCGATGGC GTGGCTGGAAAACAACCTGT TGGAGAAGGAGCTGGCTTTA ACAGCACAGCAAGAGTAACG CGTCGTCAGGTGTTTACGGT CTCGGACCATCACCACTTCT CTGCCGCATACACAAGAAGA ACAAGAACGACAAGGCCATC TGCATGGCCGTTCTTAGTTG AGCATATCTCGGCTGACGTT CCATGTGAATGATGCAGTCC AAGACACTGCCTGGTGCTCT TGAAGGGCATAAAGCAGAGC AGGCACTTCTGGAATCGACA GGCTGAGGGCATGTAATGAT TCACGTCACTGGAGAACTCG AAAACCGGAGAAGGTGGAGT AGTCTCGTTCGTTATCGGAATGA 250 152 170 177 250 175 152 166 62 Sequences are given in the 5′–3′ order. sucrose solution for 1 h at room temperature. Liver tissues were embedded in Tissue-Tek OCT compound (Sakura Finetek Japan, Tokyo, Japan) and rapidly frozen in liquid nitrogen-cooled isopentane (Wako Pure Chemicals). Frozen livers were serially sectioned at 8 µm thickness with a HM-550 cryostat (Microm, Walldorf, Germany), placed on slides, and dried at room temperature. Sections were then stained with 0.3% oil red-O (Wako Pure Chemicals) in 60% isopropanol solution for 15 min at 37 °C as described previously (Tainaka et al., 2011). Sections were visualized under a BX41 microscope (Olympus, Tokyo, Japan). 2.9. RNA extraction, cDNA synthesis, and quantitative real-time PCR Zebrafish from which total RNA was to be extracted were given a laparotomy, immediately transferred into tubes containing 3 mL of RNAlater (Qiagen, Hilden, Germany), and stored at 4 °C for gene expression analysis. Liver and visceral adipose tissues were dissected using forceps and subjected to RNA extraction. Total RNA was extracted from liver using Isogen (Nippongene, Tokyo, Japan) combined with the cleanup protocol of the RNeasy mini kit (Qiagen). Total RNA was isolated from visceral adipose tissue using the RNeasy Lipid tissue mini kit (Qiagen). This kit integrates phenol/guanidine-based sample lysis and silica-membrane purification of total RNA. Briefly, visceral adipose tissue was homogenized in 1 mL QIAzol Lysis Reagent (provided in the kit; it is a monophasic solution of phenol and guanidine thiocyanate that can facilitate lysis of fatty tissues and inhibit RNases). After incubation at room temperature (RT) for 5 min, 200 µL of chloroform (Wako Pure Chemicals) was added to the Lysis Reagent. The mixture was incubated at RT for 3 min and then centrifuged at 12,000 g at 4 °C for 15 min. A 400-µL aliquot of the aqueous phase was separated and then the same volume of 70% ethanol added to provide appropriate binding conditions. The mixture was trans- ferred to an RNeasy Mini spin column, where the total RNA bound to the membrane, and phenol and other contaminants were washed away. Total RNA was then eluted in RNasefree water. cDNA synthesis from 500 ng total RNA was performed using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). Quantitative real-time PCR (qPCR) was performed in cDNA samples using Power SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and the ABI 7300 Real-Time PCR System (Applied Biosystems) in accordance with the manufacturer’s instructions. The sequences of the sense and antisense primers used for amplification are shown in Table 2. The relative mRNA expression levels were determined using 18S rRNA as an endogenous standard. 2.10. Statistical analysis All results are presented as means and standard errors (SE). Differences between two groups were examined for statistical significance using Student’s t-test. For multiple comparisons, one-way ANOVA followed by Bonferroni–Dunn multiplecomparison procedure was used. A P-value < 0.05 was considered statistically significant. 3. Results 3.1. Yuzu peel and pomace exhibits high anti-obesity effects in DIO zebrafish Zebrafish in the DIO group exhibited a significantly higher body weight (P < 0.001) and plasma TG (P < 0.05) compared with nonDIO zebrafish, indicating successful establishment of a DIO model (Fig. 1A and 1B). The DIO group fed yuzu peel (6 mg/g/ Fig. 1 – Effects of yuzu peel and pomace on body weight, plasma TG, food intake, visceral adipose tissue volume, and lipid composition in DIO zebrafish. (A) Changes in body weight in each group during 6-week overfeeding experiments (n = 15– 20). (B) Plasma TG levels in each group (n = 15–20). (C) Food intake of each group by counting Artemia numbers before and after feeding during yuzu peel and yuzu pomace administration period. (D) Visceral adipose tissue volume in each group (n = 15–20). (E) Oil red O staining of liver sections. Red droplets indicate neutral lipid staining. Values are means ± SE. *P < 0.05, **P < 0.01 vs. the DIO group. 503 journal of functional foods 10 (2014) 499–510 A 0.7 B non-DIO DIO DIO + yuzu peel DIO + yuzu pomace 0.6 * * 800 700 600 Plasma TG (mg/dl) Body weight (g) 0.5 * 0.4 ** 0.3 ** ** ** ** ** 0.2 500 400 300 200 0.1 100 0 0 0 1 2 3 4 5 6 non-DIO DIO DIO + yuzu peel Week 6000 5000 D non-DIO DIO DIO + yuzu peel DIO + yuzu pomace Artemia numbers / fish ns 4000 ns ns ns 3000 2000 1000 4.0 * ** Visceral adipose tissue volume (mm3) C DIO + yuzu pomace 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 0 3 4 5 6 non-DIO Week E non-DIO DIO DIO + yuzu peel DIO + yuzu pomace DIO DIO + yuzu DIO + yuzu peel pomace 504 journal of functional foods 10 (2014) 499–510 day) showed a trend towards reduced diet-induced body weight gain (P = 0.13), and had significantly lower plasma TG (P < 0.05) compared with DIO zebrafish. In addition, zebrafish that received yuzu pomace (6 mg/g/day) gained significantly less body weight (P < 0.05) and showed a trend towards reduced plasma TG (P = 0.09) compared with those in the DIO group. No significant differences in feeding volume were observed between the DIO, DIO + yuzu peel, and DIO + yuzu pomace groups, indicating no appetite suppression in response to either yuzu peel or pomace during the feeding experiment (Fig. 1C). 3D micro-CT analysis (Fig. 1D) showed that visceral adipose tissue volume in the DIO group was significantly greater (P < 0.01) than that in the non-DIO group. The yuzu pomace group had significantly reduced visceral adipose tissue volume (P < 0.05) while the yuzu peel group had a trend towards a reduction of adipose tissue volume (P = 0.16) compared with DIO zebrafish. Additionally, Oil red O staining confirmed that DIO zebrafish fed yuzu peel and yuzu pomace had much lower lipid accumulation (numbers and size of red spots) in their liver compared with the DIO group (Fig. 1E). 3.2. Auraptene exhibits anti-obesity effects in DIO zebrafish Auraptene is an abundant prenyloxycoumarin found in yuzu peel. We hypothesized that auraptene might play a role in preventing lipid metabolism abnormalities induced by overfeeding. Therefore, we performed the same DIO experiment and fed DIO zebrafish a low-auraptene diet (10 µg/g/day, a 5.5-fold greater level than that found in yuzu peel) or a high-auraptene diet (20 µg/g/day, 11-fold greater than in yuzu peel), prepared as described in section 2.2. After a 4-week administration of auraptene, zebrafish in the DIO + LA group showed a slight trend towards lower body weight compared with those in the DIO group (Fig. 2A). No changes in plasma TG or appetite suppression were observed after auraptene administration during the feeding experiment (Fig. 2B and 2C). In addition, auraptene administration showed a dose-dependent trend towards lower visceral adipose tissue volume (Fig. 2D). Moreover, DIO zebrafish fed auraptene had less lipid accumulation in liver than those in the DIO group (Fig. 2E). 3.3. Effects of yuzu peel, pomace, and auraptene on the expression of lipid metabolism genes in liver and visceral adipose tissue In the liver tissue at week 6 of the experiment, there were no significant differences between the five DIO groups in the mRNA expression levels of two lipogenic enzymes, fasn or acacb, which are key enzymes for de novo fatty acid synthesis (Fig. 3). The mRNA expression levels of acadm (a mitochondrial β-oxidation enzyme, which catalyses the initial reaction in the β-oxidation of C4 to C12 straight-chain acyl-CoAs), acox1 (a peroxisomal β-oxidation enzyme, which is required for β-oxidation of longchain fatty acids), and pparab (a nuclear receptor protein that regulates β-oxidation), were significantly higher in the DIO + yuzu peel group than in the DIO group (P < 0.05). In the visceral adipose tissue, no significant differences were observed in the expression of fasn, acacb, or socs3b (a protein that suppresses leptin signalling) between the groups (Fig. 4). The expression level of pparab had a trend towards upregulation by yuzu peel but this was not statistically significant (data not shown). However, the gene expression of acox1, pparg (a regulator of adipocyte differentiation), and adipoqb (adiponectin, an antilipogenic protein) were significantly higher in the DIO + yuzu peel group compared with the DIO group (P < 0.05). 4. Discussion Yuzu has traditionally been used in cuisines, and is also used industrially in sweet production, beverages, cosmetics and perfumery. In commercial food processing, large amounts of residual yuzu are commonly discarded as industrial waste after squeezing yuzu for juice (in which case it is mainly the peel that is discarded) or after extracting essential oil from yuzu peel (in which case pomace is discarded). This is a major problem that needs to be resolved; understanding how to more completely use yuzu fruit will contribute to the reduction of this industrial waste. The primary aim of this study was to evaluate the anti-obesity effects of yuzu peel and pomace in DIO zebrafish. We demonstrated here that yuzu peel and pomace treatment exhibit powerful efficacy against body weight gain, dyslipidaemia and hepatic steatosis (Fig. 1). We thus identified a potential use for current waste products from the processing of yuzu, which may eventually enable a more complete use of yuzu and a reduction of the waste from its processing. Yuzu peel contains a wide variety of bioactive components, such as flavonoids (e.g. hesperidin, naringin and eriocitrin), anthocyanins, phenolic acids, carotenoids, tannins, vitamins, dietary fibres, and aromatics (e.g. limonene) (Nile & Park, 2014). In this study, we measured the contents of several compounds with bioactivity in yuzu peel and pomace (Table 1). Among these components, we focused on auraptene, the most abundant prenyloxycoumarin found in plants of the genus Citrus (Epifano, Genovese, & Curini, 2008). Auraptene has various notable biological functions, including anti-cancer, antiinflammatory, anti-bacterial, and angiogenic activity in vitro (Genovese & Epifano, 2011; Wang et al., 2012). Yuzu peel used in this study contained a relatively high level of auraptene (0.3 ± 0.02 mg/g dry weight), similar to that reported in a previous study (0.376 mg/g dry weight) (Ogawa et al., 2000). It has been reported that auraptene administration ameliorates Fig. 2 – Effects of low-dose auraptene (LA) and high-dose auraptene (HA) on body weight, plasma TG, food intake, visceral adipose tissue volume, and lipid composition in DIO zebrafish. (A) Changes in body weight in each group during 6-week overfeeding experiments (n = 10). (B) Plasma TG levels in each group (n = 10). (C) Food intake of each group during auraptene administration period. (D) Visceral adipose tissue volume in each group (n = 10). (E) Oil red O staining of liver sections. Values are means ± SE. *P < 0.05, **P < 0.01 vs. the DIO group. 505 journal of functional foods 10 (2014) 499–510 A 0.7 B non-DIO DIO DIO + LA DIO + HA 0.6 ns * 800 700 ** 0.4 ** 0.3 ** ** ** Plasma TG (mg/dl) Body weight (g) 600 0.5 ** 0.2 500 400 300 200 0.1 100 0.0 0 1 2 3 4 5 0 6 non-DIO DIO DIO + LA DIO + HA Week 6000 Artemia nembers / fish 5000 4.0 D non-DIO DIO DIO + LA DIO + HA ns ns ns 4000 ns 3000 2000 1000 ns ** Visceral adipose tissue volume (mm3) C 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 0 3 4 5 6 non-DIO Week E non-DIO DIO DIO + LA DIO + HA DIO DIO + LA DIO + HA 506 journal of functional foods 10 (2014) 499–510 fasn acacb 3 Relative mRNA expression level Relative mRNA expression level 3 2.5 2 1.5 1 0.5 0 2.5 2 1.5 1 0.5 0 non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace non-DIO DIO acox1 acadm 14 * 10 8 6 4 2 Relative mRNA expression level 12 Relative mRNA expression level DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace * 12 10 8 6 4 2 0 0 non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace pparab Relative mRNA expression level 16 * 14 12 10 8 6 4 2 0 non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace Fig. 3 – Effects of yuzu peel, pomace, and auraptene on the expression of lipid metabolism genes in liver. fasn and acacb play important roles in lipogenesis. acadm, acox1 and pparab are closely related to fatty acid oxidation (n = 5). Values are means ± SE. *P < 0.05 vs. the DIO group. 507 journal of functional foods 10 (2014) 499–510 fasn acacb 3 Relative mRNA expression level Relative mRNA expression level 3 2.5 2 1.5 1 0.5 0 2.5 2 1.5 1 0.5 0 non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace non-DIO DIO acox1 socs3b 7 Relative mRNA expression level Relative mRNA expression level 1.6 1.4 1.2 1 0.8 0.6 0.4 DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace * 6 5 4 3 2 1 0.2 0 0 non-DIO DIO non-DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace DIO adipoqb pparg 7 30 6 ** 5 4 3 2 1 Relative mRNA expression level Relative mRNA expression level DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace * 25 20 15 10 5 0 0 non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace non-DIO DIO DIO + LA DIO + HA DIO + yuzu DIO + yuzu peel pomace Fig. 4 – Effects of yuzu peel, pomace, and auraptene on the expression of lipid metabolism genes in visceral adipose tissue. socs3b is a negative regulator of leptin signalling. pparg and adipoqb play roles in adipose differentiation (n = 5). Values are means ± SE. *P < 0.05 vs. the DIO group, **P < 0.01 vs. the DIO group. 508 journal of functional foods 10 (2014) 499–510 hepatic TG accumulation in the livers of obese rats (Nagao et al., 2010), which is consistent with our results in zebrafish livers (Fig. 2E). However, there were no significant differences in plasma TG levels or adipose tissue volume between the auraptene group and the DIO group (Fig. 2B and 2D). This suggests that the therapeutic property of auraptene is limited to improvement of hepatosteatosis, but not of systemic lipid metabolism including visceral adiposity. In addition to auraptene, some bioactive molecules in yuzu peel have been reported to induce PPAR mRNA expression with consequent anti-obesity properties. For example, limonene protected against the development of dyslipidaemia by activating PPARα transactivation in obese mice (Jing et al., 2013). Hesperidin and naringin are the most abundant flavonoids in yuzu fruit (Nile & Park, 2014). The amounts of these flavonoids can be affected by various factors, such as production area, measurement site and stage of maturation. We found that hesperidin and naringin levels were high in our Japanese yuzu peel (92.57 ± 0.15 and 52.23 ± 0.21 mg/100 g fresh weight, respectively); these levels are similar to those observed in Korean yuzu peel (74.47–96.24 and 81.51–98.1 mg/100 g fresh weight, respectively) (Yoo et al., 2004). Hesperidin and naringin attenuated hyperlipidaemia and hepatic steatosis, partly by regulating fatty acid and cholesterol metabolism through enhancing hepatic and adipocyte PPARγ expression in type-2 diabetic animals (Jung, Lee, Park, Kang, & Choi, 2006; Sharma et al., 2011). In this study, administration of yuzu peel increased the mRNA expression of markers of lipid oxidation (pparab and acadm in liver, pparg in adipose tissue, and acox1 in both) and mature adipocytes (adipoqb in adipose tissue) in DIO zebrafish without affecting markers of lipogenesis (fasn and acacb in adipose tissue and liver) (Figs 3 and 4). It is well known that activation of PPARα (the human homolog of zebrafish pparab) causes lipid clearance via enhancement of fatty acid β-oxidation in liver (Berger, Akiyama, & Meinke, 2005; Kersten, 2002). The expression levels of PPARα target genes (ACOX1 and ACADM) were also enhanced which consequently promote mitochondrial and peroxisomal fatty acid β-oxidation pathway to increase lipolysis (Rakhshandehroo, Knoch, Muller, & Kersten, 2010). PPARγ (the human homolog of zebrafish pparg) is predominantly expressed in adipose tissue and is critical for adipocyte differentiation, maintenance, and regulation of adipose tissue lipid metabolism (Spiegelman, 1998). In addition, PPARγ activates the transcription of ADIPOQ (the human homolog of zebrafish adipoqb) (Lee, Olson, & Evans, 2003), which plays a role in energy homeostasis through the regulation of fatty acid metabolism in muscle and liver (Berg, Combs, & Scherer, 2002). These observations suggest that the systemic anti-dyslipidaemia effect of yuzu peel is dependent on the PPARγ-ADIPOQ axis, which may be conserved in vertebrates. Our results suggest that various bioactive compounds in yuzu peel can improve dyslipidaemia and hepatic steatosis via activation of hepatic PPARα and adipocyte PPARγ pathways. It is notable that yuzu pomace also improved visceral adiposity and hepatic steatosis (Fig. 1D and 1E), while the gene expression profiles are different from those of the peel group. Yuzu contains an almost threefold greater amount of total dietary fibre than other citrus fruits (Yoo, Hwang, Park, & Moon, 2009). The content of dietary fibre in yuzu pomace was higher than in peel (8.35 ± 0.08 and 6.4 ± 0.02 g/100 g fresh weight, respectively) (Table 1). It is well known that dietary fibre can suppress body weight gain in obese people, because of its low digestibility and low absorption (Fukada, Furutani, Shimizu, & Masumoto, 2013; Lattimer & Haub, 2010). In addition, while most of the auraptene and limonene were lost after hexane extraction, both hesperidin and naringin remained and were further concentrated (Table 1). The greater amount of fibre in combination with hesperidin and naringin in pomace may have helped to suppress the body weight increase in the DIO group, which was not seen in response to yuzu peel (Fig. 1A). Furthermore, we applied yuzu pomace to cultured red seabream (Pagrus major), and found that yuzu pomace-supplemented bait prevented dark muscle discoloration and decreased white adipose tissue weight (data not shown). Overall, our results suggest a possible application of yuzu peel or pomace for reducing obesity and related diseases, making use of material which is currently disposed of as industrial waste. 5. Conclusions Using DIO zebrafish, we clarified the anti-obesity effects of yuzu peel, pomace and the bioactive component auraptene. We established that the therapeutic mechanism of yuzu peel is through activation of hepatic PPARα and adipocyte PPARγ pathways. Our findings demonstrate that yuzu peel may be an ideal natural product with actions against obesity and related diseases. In addition, we showed that yuzu pomace is effective in obesity phenotypes, which suggests a novel use for citrus fruit pomace. This study is the first to identify new approaches to achieve the complete use of yuzu, and thus provides a valuable insight into improving the processing of citrus fruit to reduce waste. Acknowledgements This work was supported in part by Grants-in-Aid for Scientific Research in Japan (KAKENHI 25860294 and 25590073). The authors would like to thank Tsuji Oil Mill Co., Ltd for supplying information, Mr. Junya Kuroyanagi and Ms. Mari Suzuki for assistance with the zebrafish feeding experiment, and Mrs. Asaka Uechi and Mrs. Eriko Nakanishi for secretarial assistance. Appendix: Supplementary material Supplementary data to this article can be found online at doi:10.1016/j.jff.2014.08.002. REFERENCES Ajila, C. M., & Rao, U. J. S. P. (2013). Mango peel dietary fibre: Composition and associated bound phenolics. Journal of Functional Foods, 5, 444–450. journal of functional foods 10 (2014) 499–510 AOAC Official Methods of Analysis (2000). Method No. 985.29, enzymatic gravimetric analysis (p. 78). Aronne, L. J., Powell, A. G., & Apovian, C. M. (2011). Emerging pharmacotherapy for obesity. Expert Opinion on Emerging Drugs, 16, 587–596. Berg, A. H., Combs, T. P., & Scherer, P. E. (2002). ACRP30/ adiponectin: An adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism, 13, 84–89. Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005). PPARs: Therapeutic targets for metabolic disease. Trends in Pharmacological Sciences, 26, 244–251. Bessesen, D. H. (2008). Update on obesity. Journal of Clinical Endocrinology and Metabolism, 93, 2027–2034. Choi, H. S. (2006). Lipolytic effects of citrus peel oils and their components. Journal of Agricultural and Food Chemistry, 54, 3254–3258. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet, 370, 1706–1713. Epifano, F., Genovese, S., & Curini, M. (2008). Auraptene: Phytochemical and pharmacological properties. In M. Takumi (Ed.), Phytochemistry research progress (pp. 145–162). Nova Science Publishers, Inc. Fukada, H., Furutani, T., Shimizu, R., & Masumoto, T. (2013). Effects of yuzu (Citrus junos) peel from waste as an aquaculture feed supplement on growth, environmental load, and dark muscle discoloration in yellowtail Seriola quinqueradiata. Journal of Aquatic Food Product Technology. Genovese, S., & Epifano, F. (2011). Auraptene: A natural biologically active compound with multiple targets. Current Drug Targets, 12, 381–386. Haslam, D. W., & James, W. P. (2005). Obesity. Lancet, 366, 1197– 1209. Hasumura, T., Shimada, Y., Kuroyanagi, J., Nishimura, Y., Meguro, S., Takema, Y., & Tanaka, T. (2012). Green tea extract suppresses adiposity and affects the expression of lipid metabolism genes in diet-induced obese zebrafish. Nutrition & Metabolism, 9, 73–79. Hirai, S., Takahashi, N., Goto, T., Lin, S., Uemura, T., Yu, R., & Kawada, T. (2010). Functional food targeting the regulation of obesity-induced inflammatory responses and pathologies. Mediators of Inflammation, 2010, 367838. Hiramitsu, M., Shimada, Y., Kuroyanagi, J., Inoue, T., Katagiri, T., Zang, L., Nishimura, Y., Nishimura, N., & Tanaka, T. (2014). Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis. Scientific Reports, 4, 3708. Hirota, R., Roger, N. N., Nakamura, H., Song, H. S., Sawamura, M., & Suganuma, N. (2010). Anti-inflammatory effects of limonene from yuzu (Citrus junos Tanaka) essential oil on eosinophils. Journal of Food Science, 75, H87–H92. Jing, L., Zhang, Y., Fan, S., Gu, M., Guan, Y., Lu, X., Huang, C., & Zhou, Z. (2013). Preventive and ameliorating effects of citrus d-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity. European Journal of Pharmacology, 715, 46–55. Jung, U. J., Lee, M. K., Park, Y. B., Kang, M. A., & Choi, M. S. (2006). Effect of citrus flavonoids on lipid metabolism and glucoseregulating enzyme mRNA levels in type-2 diabetic mice. International Journal of Biochemistry & Cell Biology, 38, 1134–1145. Kersten, S. (2002). Peroxisome proliferator activated receptors and obesity. European Journal of Pharmacology, 440, 223–234. Kim, S. H., Hur, H. J., Yang, H. J., Kim, H. J., Kim, M. J., Park, J. H., Sung, M. J., Kim, M. S., Kwon, D. Y., & Hwang, J. T. (2013). Citrus junos Tanaka peel extract exerts antidiabetic effects via AMPK and PPAR-gamma both in vitro and in vivo in mice fed a 509 high-fat diet. Evidence-based Complementary and Alternative Medicine, 2013, 921012. Kim, S. H., Shin, E. J., Hur, H. J., Park, J. H., Sung, M. J., Kwon, D. Y., & Hwang, J. T. (2014). Citrus junos Tanaka peel extract attenuates experimental colitis and inhibits tumour growth in a mouse xenograft model. Journal of Functional Foods, 8, 301– 308. Lattimer, J. M., & Haub, M. D. (2010). Effects of dietary fiber and its components on metabolic health. Nutrients, 2, 1266–1289. Lee, C. H., Olson, P., & Evans, R. M. (2003). Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferatoractivated receptors. Endocrinology, 144, 2201–2207. Lesjak, M. M., Beara, I. N., Orcic, D. Z., Petar, K. N., Simin, N. D., Emilija, S. D., & Mimica-Dukic, N. M. (2014). Phytochemical composition and antioxidant, anti-inflammatory and antimicrobial activities of Juniperus macrocarpa Sibth. et Sm. Journal of Functional Foods, 7, 257–268. Lieschke, G., & Currie, P. (2007). Animal models of human disease: Zebrafish swim into view. Nature Reviews. Genetics, 8, 353–367. Matthews, M., & Varga, Z. M. (2012). Anesthesia and euthanasia in zebrafish. ILAR Journal, 53, 192–204. Miyake, Y. (2006). Characteristics of flavonoids in niihime fruit – A new sour citrus fruit. Food Science and Technology Research, 12, 186–193. Nagao, K., Yamano, N., Shirouchi, B., Inoue, N., Murakami, S., Sasaki, T., & Yanagita, T. (2010). Effects of citrus auraptene (7geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. Journal of Agricultural and Food Chemistry, 58, 9028–9032. Nile, S. H., & Park, S. W. (2014). Bioactive components and health promoting properties of yuzu (Citrus ichangensis× C. reticulate): A review. Food Reviews International, 30, 155–167. Ogawa, K., Kawasaki, A., Yoshida, T., Nesumi, H., Nakano, M., Ikoma, Y., & Yano, M. (2000). Evaluation of auraptene content in citrus fruits and their products. Journal of Agricultural and Food Chemistry, 48, 1763–1769. Oka, T., Nishimura, Y., Zang, L., Hirano, M., Shimada, Y., Wang, Z., Umemoto, N., Kuroyanagi, J., Nishimura, N., & Tanaka, T. (2010). Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiology, 10, 21. Rakhshandehroo, M., Knoch, B., Muller, M., & Kersten, S. (2010). Peroxisome proliferator-activated receptor alpha target genes. PPAR Research, 2010. Sawamura, M., Wu, Y., Fujiwara, C., & Urushibata, M. (2005). Inhibitory effect of yuzu essential oil on the formation of N-nitrosodimethylamine in vegetables. Journal of Agricultural and Food Chemistry, 53, 4281–4287. Sharma, A. K., Bharti, S., Ojha, S., Bhatia, J., Kumar, N., Ray, R., Kumari, S., & Arya, D. S. (2011). Up-regulation of PPARγ, heat shock protein-27 and -72 by naringin attenuates insulin resistance, beta-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. British Journal of Nutrition, 106, 1713–1723. Shimada, Y., Hirano, M., Nishimura, Y., & Tanaka, T. (2012). A high-throughput fluorescence-based assay system for appetite-regulating gene and drug screening. PLoS ONE, 7, e52549. Shimada, Y., Kuroyanagi, J., Zhang, B., Ariyoshi, M., Umemoto, N., Nishimura, Y., & Tanaka, T. (2013). Downregulation of Max dimerization protein 3 is involved in decreased visceral adipose tissue by inhibiting adipocyte differentiation in zebrafish and mice. International Journal of Obesity. Spiegelman, B. M. (1998). PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes, 47, 507–514. Stoletov, K., Fang, L., Choi, S. H., Hartvigsen, K., Hansen, L. F., Hall, C., Pattison, J., Juliano, J., Miller, E. R., Almazan, F., Crosier, P., Witztum, J. L., Klemke, R. L., & Miller, Y. I. (2009). Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid 510 journal of functional foods 10 (2014) 499–510 uptake in hypercholesterolemic zebrafish. Circulation Research, 104, 952–960. Tainaka, T., Shimada, Y., Kuroyanagi, J., Zang, L., Oka, T., Nishimura, Y., Nishimura, N., & Tanaka, T. (2011). Transcriptome analysis of anti-fatty liver action by Campari tomato using a zebrafish diet-induced obesity model. Nutrition & Metabolism, 8, 88. Wang, S. Y., Yoon, Y. C., Sung, M. J., Hwang, J. T., Hur, H. J., Kim, H. J., Yang, H. J., Kim, M. S., Kwon, D. Y., & Park, J. H. (2012). Citrusderived auraptene stimulates angiogenesis by activating the Erk- and PI3K/Akt/eNOS-dependent signaling pathways in human umbilical vein endothelial cells. Journal of Functional Foods, 4, 899–905. Westerfield, M. (2007). The zebrafish book: A guide for the laboratory use of zebrafish (Danio rerio). Eugene: University of Oregon Press. WHO (2013). Obesity and overweight. Fact sheet NO. 311. Geneva, Switzerland: World Health Organization. Yoo, K. M., Hwang, I. K., Park, J. H., & Moon, B. (2009). Major phytochemical composition of 3 native Korean citrus varieties and bioactive activity on V79-4 cells induced by oxidative stress. Journal of Food Science, 74, C462–C468. Yoo, K. M., Lee, K. W., Park, J. B., Lee, H. J., & Hwang, I. K. (2004). Variation in major antioxidants and total antioxidant activity of Yuzu (Citrus junos Sieb ex Tanaka) during maturation and between cultivars. Journal of Agricultural and Food Chemistry, 52, 5907–5913. Yun, J. W. (2010). Possible anti-obesity therapeutics from nature – A review. Phytochemistry, 71, 1625–1641. Zang, L., Morikane, D., Shimada, Y., Tanaka, T., & Nishimura, N. (2011). A novel protocol for the oral administration of test chemicals to adult zebrafish. Zebrafish, 8, 203–210. Zang, L., Shimada, Y., Nishimura, Y., Tanaka, T., & Nishimura, N. (2013). A novel, reliable method for repeated blood collection from aquarium fish. Zebrafish, 10, 425–432.